IL17A and Insulin resistance: None of the treamtents exerted signficant anti-inflammatory effects on IL-1β, IL-12 or IL-17, and homeostatic model assessement of insulin-resistance (HOMA-IR) remained similar among all groups, which suggests that none of the treatments reduced inflammation or enhanced tissue sensitivity to insulin (Fig 3).